| |
Moving Forward
By Going Traditional: Benda Pharmaceutical (BPMA:OTCBB)
By Glenn Wilkins -
AllPennyStocks.com News Reporter
October 29, 2007 (AllPennyStocks.com
Media, Inc.) – Marvelous advances have been made in recent
memory in the fight against cancer. One of the most noteworthy
has come from behind what we used to call the “Bamboo
Curtain”, in a modern China more accustomed than before to
opening medical and commercial gates to the West.
It’s called Gendicine, the world’s first commercialized gene
therapy medicine for the treatment of cancer, and the flagship
medicine among the dozens distributed by Benda Pharmaceutical.
Benda Pharmaceutical, Inc.
(OTCBB:BPMA), headquartered in North America in the
Pacific Northwest and British Columbia, is a China-based
pharmaceutical company, a pure play on explosive Chinese drug
company spending and the global search for a cancer cure.
Benda is involved in the production of both conventional as
well as cutting edge gene therapy Chinese medicines. The
company owns and operates five plants, combining to produce
more than 30 medicines and medicine ingredients.
If necessity is the Mother of invention, as Aesop told us, the
scourge of cancer is driving the spread of this radical, yet
somewhat traditional, treatment.
China is currently facing skyrocketing cancer and heart
disease rates, as well as an aging population, and is in the
process of reforming its health-care system, in hopes of
making access to drugs and treatment more affordable. China
has the potential to become the world’s fifth largest drug
market within three years.
Benda acquired the distribution rights to Gendicine through
its acquisition of SiBiono Genentech Corporation, the company
that developed the drug. The company says that Gendicine,
supplemented by radiotherapy, chemotherapy or heat treatment,
raises the effectiveness of treatment to three times that of
all other treatment methods.
Clinical trials showed that 64 per cent of tested patients
with head and neck tumors saw those tumors eliminated within a
month of taking the treatment. Scientific journals such as
Nature, reporting on these tests, said that as of last July,
Gendicine had been given to more than 6,000 patients, 400 of
them in the West. The treatment was also seen to be safe, with
no extreme immune responses reported.
After the test results were made public in September, the
floodgates opened, at least in the home county. Such
enthusiasm greeted the tests in China that physicians who were
on hand placed orders for 16,000 vials of Gendicine,
effectively buying out all available product in just one day.
Sales of the product are expected to top $3.8 million.
The SiBiono plants which manufacture Gendicine have a capacity
of 150,000 doses of the drug per year, which is likely to
increase next year after the company moves to a large new
production facility – more reason for investors to get
excited.
The company is aiming toward the future with confidence, based
on a solid past among its uppermost managers. CEO and
Co-Founder Yiqing Wan comes with 20 years’ experience in
pharmaceutical marketing and production end of things;
Director and CFO Eric Yu has 13 years behind him in the
corporate accounting and financial field, having taken his
degree from universities in Australia; Vice-President of
Operation Zhaohui Peng, who founded SiBiono, took his PhD in
biological chemistry in Japan, and did post doctorate work at
UCLA. Dr. Peng has devoted more than 15 years to gene therapy
research and development, industrialization and
commercialization. Benda co-founder Wei Yu has at her back 25
years’ experience in pharmaceutical marketing.
Benda, whose stock trades on the Over-The-Counter market under
the symbol BPMA, is working to build its presence within the
fast-growing Chinese market. The company forecasts that
Gendicine alone will generate $12.7 million in revenues this
year, more than $20 million next (all figures in U.S. dollars
unless specified otherwise). Overall revenues are foreseen to
reach $40.7 million in 2007 and top $76 million in 2008.
Small cap investors with an eye for value could find this an
exciting time for poring into the recent fortunes and the
immediate prospects for BPMA. With the recent popularity of
Gendicine among the medical community, and the potentially
huge market for the product in one of the biggest markets on
earth, this stock could find itself going places. Considering
it was this time last year that the price lay in a 52-week
gulch of 41 cents, BPMA has shown remarkable resilience,
climbing to a peak of $3.00 in late June and early July,
before settling into its current range of between $2.20 and
$2.40.
Some trading days in October saw the stock change hands in the
area of 180,000 shares. The company is hoping to preserve this
momentum going forward, as the product helps ease fears of the
scourge of cancer, within China and worldwide.
Copyright © 2007 AllPennyStocks.com. All
rights reserved. Republication or redistribution of
AllPennyStocks.com's content is expressly prohibited without
the prior written consent of AllPennyStocks.com.
AllPennyStocks.com shall not be liable for any errors or
delays in the content, or for any actions taken in reliance
thereon.
Although the majority of
AllPennyStocks.com reports are independent, it has received
compensation for carrying the report on Benda Pharmaceutical,
Inc., the compensation is seventeen thousand seven hundred and
fifty dollars by the company. This creates an inherent
conflict of interest and readers are encouraged to view the
main disclaimer at
/aps_us/company_spotlights/archives/bpma.asp
|
|
